AstraZeneca PLC (AZN.L)
LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
As of 12:41PM BST. Market open.
| Previous close | 11,964.00 |
| Open | 11,826.00 |
| Bid | 11,762.00 x 0 |
| Ask | 11,766.00 x 0 |
| Day's range | 11,754.00 - 11,922.00 |
| 52-week range | 9,461.00 - 13,388.00 |
| Volume | |
| Avg. volume | 1,841,121 |
| Market cap | 182.314B |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | 37.81 |
| EPS (TTM) | 3.11 |
| Earnings date | 12 Nov 2024 |
| Forward dividend & yield | 2.34 (1.95%) |
| Ex-dividend date | 08 Aug 2024 |
| 1y target est | 133.44 |
Yahoo Finance UKHow to minimise a capital gains tax impact on your investments
Multi-asset funds have been put forward as one way to manage the impact of a mooted capital gains tax hike on investment portfolios.
ZacksAstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded Use
The FDA grants priority review to AZN's sNDA for Calquence for untreated mantle cell lymphoma. A decision is expected in first-quarter 2025.
Business WireCALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma
WILMINGTON, Del., October 03, 2024--AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL).
© 2024 Yahoo. All rights reserved.